此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项研究米塔皮伐在输血依赖性α-或β-地中海贫血(α-或β-TDT)儿科受试者中的疗效、药代动力学和安全性 (ENERGIZEKids-T)

2026年10月28日 更新者:Agios Pharmaceuticals, Inc.

一项评估Mitapivat在α-或β-输血依赖性地中海贫血儿科受试者中的疗效、药代动力学和安全性的第3期、双盲、随机、安慰剂对照、多中心研究

The primary objective of this study is to compare the effect of mitapivat versus placebo on transfusion burden in pediatric participants with α- or β-transfusion-dependent thalassemia.

研究概览

研究类型

介入性

注册 (估计的)

54

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Agios Medical Affairs
  • 电话号码:833-228-8474
  • 邮箱:medinfo@agios.com

学习地点

    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital
    • New York
      • New York、New York、美国、10065
        • 招聘中
        • Weill Cornell Medical College/ New York Presbyterian
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104-4318
        • 招聘中
        • Children's Hospital of Philadelphia
    • Texas
      • Dallas、Texas、美国、75390
        • 招聘中
        • University of Texas Southwestern Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 至 17年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Written informed consent/assent from the participant (or their legally authorized representative, parent(s), or legal guardian) must be obtained before any study-related procedures are conducted and participants must be willing to comply with all study procedures for the duration of the study.
  • Aged 1 to <18 years and weighing at least 7 kilograms (kg) at the time of providing informed consent/assent.
  • Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, hemoglobin E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H (HbH) disease) based on Hemoglobin (Hb) electrophoresis, Hb high-performance liquid chromatography, and/or DNA analysis from the participant's medical record. If this information is not available from the participant's medical record, the test(s) can be performed by a local laboratory during the Screening Period. If a local laboratory is unable to perform the test(s), results from the comprehensive α- and β-globin genotyping performed by the study central laboratory can be used.
  • Transfusion dependent, defined as 6 to 20 transfusion episodes (also referred to as "transfusion events") and a ≤6-week transfusion-free period during the 24-week period before randomization.
  • If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before randomization.
  • Female participants who have attained menarche must be abstinent of sexual activities that may induce pregnancy as part of their usual lifestyle, or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of informed consent/assent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can include an acceptable barrier method.

Exclusion Criteria:

  • Pregnant or breastfeeding.

  • Documented history of homozygous or heterozygous hemoglobin S (HbS) or hemoglobin C (HbC).

  • Prior exposure to gene therapy or prior bone marrow or stem cell transplantation, including any prior exposure to myeloablative chemotherapy.

  • Any conditions other than thalassemia expected to affect sexual maturation.

  • Currently receiving treatment with luspatercept; the last dose must have been administered ≥36 weeks before randomization.

  • Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered ≥36 weeks before randomization.

  • History of malignancy (active or treated) ≤5 years before providing informed consent/assent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ.

  • History of active and/or uncontrolled cardiac or pulmonary disease or clinically relevant QT prolongation within 6 months before providing informed consent/assent.

  • Hepatobiliary disorders, including but not limited to:

    • Liver disease with histopathological evidence or clinical diagnosis of cirrhosis or severe fibrosis.
    • Clinically symptomatic cholelithiasis or cholecystitis (prior cholecystectomy is not exclusionary).
    • History of drug-induced cholestatic hepatitis.
    • Aspartate Aminotransferase (AST) >2.5*Upper Limit of Normal (ULN) (unless due to hemolysis and hepatic iron deposition) and Alanine Transaminase (ALT) >2.5*ULN (unless due to hepatic iron deposition).
  • Renal dysfunction as defined by an estimated glomerular filtration rate <60 milliliters per minute (mL/min)/1.73-meter square (m^2).

  • Nonfasting triglycerides >215 milligrams per deciliter (mg/dL) [5 millimole per liter (mmol/L)].

  • Active infection requiring systemic antimicrobial therapy at the time of providing informed consent/assent. If antimicrobial therapy is required during the Screening Period, screening procedures should not be performed while antimicrobial therapy is being administered, and the last dose of antimicrobial therapy must be administered ≥7 days before randomization.

  • Participants with known active hepatitis B or hepatitis C virus infection.

  • Participants with known human immunodeficiency virus (HIV) infection.

  • History of major surgery (including splenectomy) ≤ 6 months before providing informed consent/assent and/or a major surgical procedure planned during the study.

  • Current enrollment or past participation (within ≤12 weeks or a timeframe equivalent to 5 half-lives of the investigational study drug before administration of the first dose of study drug, whichever is longer) in any other clinical study involving an investigational treatment or device.

  • Receiving strong Cytochrome3A4/5 (CYP3A4/5) inhibitors that have not been stopped for ≥5 days or a timeframe equivalent to 5 half-lives (whichever is longer), or strong CYP3A4/5 inducers that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives (whichever is longer), before randomization.

  • Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed; the testosterone dose and preparation must be stable for ≥12 weeks before randomization.

  • Known allergy, or other contraindication, to mitapivat or its excipients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, magnesium stearate, and the Opadry filmcoat [hypromellose, titanium dioxide, lactose monohydrate triacetin, and FD&C Blue #2]).

  • Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:

    • Participants who are institutionalized by regulatory or court order.
    • Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Mitapivat

Participants will receive oral mitapivat twice daily (BID), with dose determined by age and weight, for 48 weeks during the double blind (DB) period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort.

Cohort 1: 12 to <18 years

Cohort 2: 6 to <12 years

Cohort 3: 1 to <6 years

Participants who complete the DB period may continue receiving mitapivat in the open label extension (OLE) period for up to 144 weeks.

Tablets or Granules

其他名称:
  • AG-348
  • 硫酸米匹伐特
安慰剂比较:Placebo

Participants will receive oral placebo matching mitapivat, administered BID, with dosing based on age and weight, for 48 weeks during the DB period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort.

Cohort 1: 12 to <18 years

Cohort 2: 6 to <12 years

Cohort 3: 1 to <6 years

Participants who complete the DB period may transition to receive mitapivat in the OLE period for up to 144 weeks.

Tablets or Granules

其他名称:
  • AG-348
  • 硫酸米匹伐特

Tablets or Granules

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) Through Week 48
大体时间:Baseline, through Week 48

TRR is defined as ≥50 percent (%) reduction in transfused red blood cells (RBC) volume (normalized by weight) in any consecutive 12-week period through Week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks.

Baseline, through Week 48

次要结果测量

结果测量
措施说明
大体时间
从第13周至第48周,输血红细胞容量变化百分比(按体重标准化)与历史输血容量(按体重标准化)相比,并标准化至36周
大体时间:基线,第13周至第48周
基线,第13周至第48周
与标准化至36周的历史输血发作次数相比,从第13周至第48周输血发作次数的变化
大体时间:基线,第13周至第48周
基线,第13周至第48周
第48周时血清铁相对于基线的变化
大体时间:基线,第48周
基线,第48周
第48周总铁结合力相对基线的变化
大体时间:基线, 第48周
基线, 第48周
第48周转铁蛋白相对于基线的变化
大体时间:基线,第48周
基线,第48周
第48周转铁蛋白饱和度相对于基线的变化
大体时间:基线,第48周
基线,第48周
第48周血清铁蛋白水平相对基线的变化
大体时间:基线,第48周
基线,第48周
队列1:从基线至第48周雌二醇的变化
大体时间:基线至第48周
基线至第48周
队列1:从基线至第48周雌酮的变化
大体时间:基线至第48周
基线至第48周
队列 1:第 48 周总睾酮相对于基线的变化
大体时间:基线至第48周
基线至第48周
队列 1:第 48 周时游离睾酮相对于基线的变化
大体时间:基线至第48周
基线至第48周
队列 1:第 48 周时黄体生成素相对于基线的变化
大体时间:基线至第48周
基线至第48周
队列1:从基线至第48周性成熟等级(坦纳分期)的变化
大体时间:基线至第48周
基线至第48周
第48周期间身高年龄Z评分、体重年龄Z评分和体重指数(BMI)年龄Z评分相对于基线的变化
大体时间:基线至第48周
基线至第48周
从基线至第48周骨矿物质密度(BMD)的变化
大体时间:基线期至第48周
基线期至第48周
出现治疗期间不良事件(AEs)和严重不良事件(SAEs)的参与者人数
大体时间:从首次研究药物给药至研究结束(最长至第196周)
从首次研究药物给药至研究结束(最长至第196周)
米塔匹伐的血浆浓度
大体时间:给药前,以及第4周给药后多个时间点(最长至给药后7小时)
给药前,以及第4周给药后多个时间点(最长至给药后7小时)
米塔帕韦血浆浓度-时间曲线下面积(从零时至最后可定量浓度的时间点)
大体时间:给药前,以及第4周给药后多个时间点(最长至给药后7小时)
给药前,以及第4周给药后多个时间点(最长至给药后7小时)
米他匹韦的最大观察血浆浓度(Cmax)
大体时间:第4周给药前及给药后多个时间点(最长至给药后7小时)
第4周给药前及给药后多个时间点(最长至给药后7小时)
米塔吡伐达到最大观察血浆浓度所需时间(Tmax)
大体时间:给药前,以及第4周给药后多个时间点(最长7小时)
给药前,以及第4周给药后多个时间点(最长7小时)
队列1:截至第48周新发生卵巢囊肿的女性参与者百分比
大体时间:基线至第48周
基线至第48周
Percentage of Participants Who Achieved TRR2 From Week 13 to Week 24
大体时间:Baseline, Week 13 through Week 24

TRR2 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 13 to week 24 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks.

Baseline, Week 13 through Week 24
Percentage of Participants Who Achieved TRR3 From Week 25 to Week 36
大体时间:Baseline, Week 25 through Week 36

TRR3 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 25 to week 36 compared with historical RBC transfusion volume (Normalized by Weight) and standardized to 12 weeks.

Baseline, Week 25 through Week 36
Percentage of Participants Who Achieved TRR4 From Week 37 to Week 48
大体时间:Baseline, Week 37 through Week 48

TRR4 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 37 to week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks.

Baseline, Week 37 through Week 48
Percentage of Participants Who Achieved TRR5 From Week 25 to Week 48
大体时间:Baseline, Week 25 through Week 48

TRR5 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 25 to week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 24 weeks.

Baseline, Week 25 through Week 48
Percentage of Participants Who Achieved Transfused Independence Through Week 48
大体时间:Baseline, through Week 48

Transfusion independence is defined as transfusion-free for greater than or equal to 8 consecutive weeks through Week 48.

Baseline, through Week 48

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月24日

初级完成 (估计的)

2029年6月1日

研究完成 (估计的)

2032年6月1日

研究注册日期

首次提交

2026年3月26日

首先提交符合 QC 标准的

2026年3月26日

首次发布 (实际的)

2026年4月2日

研究记录更新

最后更新发布 (实际的)

2026年10月29日

上次提交的符合 QC 标准的更新

2026年10月28日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • AG348-C-029
  • 2025-524707-71-00 (克蒂斯)
  • 2025 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅